The condition at the heart of the analysis is metabolic dysfunction-associated steatotic liver disease, or MASLD, which affects roughly a third of adults in many industrialized countries. In a subset of patients, simple fat accumulation progresses to metabolic dysfunction-associated steatohepatitis, or MASH, an inflammatory state marked by hepatocyte injury, fibrosis, and regenerative nodules. MASH is now one of the fastest-growing substrates for hepatocellular carcinoma worldwide, and alarmingly, it can give rise to liver cancer even in the absence of full-blown cirrhosis. Yet as the review emphasizes, the cancer biology of this pathway cannot be reduced to fat simply piling up inside liver cells.

The authors organize their argument around a phase-resolved framework that divides the MASLD-to-cancer continuum into three biologically distinct stages. In the earliest phase, the problem is one of lipid-buffering failure. The liver receives an oversupply of fatty substrates from the diet and from adipose tissue while simultaneously ramping up de novo lipogenesis, the internal synthesis of new fat from excess carbohydrates. Transcription factors such as sterol regulatory element-binding protein 1c and carbohydrate response element-binding protein drive this synthesis, while enzymes including ATP citrate lyase, acetyl-CoA carboxylase, and fatty acid synthase execute it. When fatty acid oxidation cannot keep pace and very-low-density lipoprotein export falters, triglycerides accumulate, organelles become stressed, and the gut-liver axis delivers inflammatory microbial products that amplify the damage.

What makes this framework provocative is its insistence that the same lipid pathway can be protective in one phase and oncogenic in another. Lipid droplets, for instance, are often dismissed as mere storage depots, but they can act as safety buffers that sequester toxic lipids away from sensitive membranes. Perilipin proteins that coat these droplets help determine whether stored fat remains inert or becomes dangerous. During the transformation phase, however, repeated cycles of lipotoxic injury convert metabolic stress into genomic damage. Reactive oxygen species generated by overloaded mitochondria and stressed endoplasmic reticulum attack DNA directly, while the review highlights how senescence escape, epigenetic reprogramming, and RNA-level stress memory consolidate the malignant potential of injured hepatocytes.

The molecular cast of characters in this transformation is extensive. The review catalogs alterations in DNA damage checkpoint mediators, chromatin remodelers such as Brahma-related gene 1, and RNA modification machinery including the methyltransferase METTL14, which deposits N6-methyladenosine marks on messenger RNA. Fibrotic remodeling driven by hepatic stellate cells creates a permissive microenvironment, while immune dysfunction, including impaired antitumor T cell surveillance and altered mucosal-associated invariant T cell function, removes another layer of defense. The gut microbiome contributes its own amplification loop, with microbial metabolites such as trimethylamine N-oxide and deoxycholic acid species feeding back into hepatic inflammation and proliferation signals.

Once hepatocellular carcinoma is established, the metabolic logic shifts again. Malignant cells become connoisseurs of fat, exploiting a suite of lipid programs to fuel growth and resist therapy. They upregulate de novo lipogenesis to build membranes for dividing cells, deploy selective fatty acid oxidation as an efficient energy source, and reroute carnitine shuttling through transporters such as organic cation and carnitine transporter 2 and carnitine palmitoyltransferase 1A to keep mitochondria supplied. Fatty acid uptake via the scavenger receptor CD36 and lipid droplet buffering through hypoxia-inducible lipid droplet-associated protein allow tumors to thrive under hypoxic conditions where normal cells would falter.

Perhaps the most clinically consequential theme in the review is ferroptosis resistance. Ferroptosis is an iron-dependent form of cell death driven by the peroxidation of membrane lipids, and it has emerged as a promising vulnerability in cancer therapy. Lipid-rich liver tumors, however, appear to have evolved multiple countermeasures. The review describes how enzymes such as acyl-CoA synthetase family members and phospholipase A2 group VI, along with antioxidant regulators like glutathione peroxidase 4 and the cystine transporter SLC7A11, help malignant hepatocytes neutralize lipid peroxides before they become lethal. Understanding these defenses, the authors argue, is essential for designing therapies that can flip the switch back toward ferroptotic death.

This phase dependency also exposes a subtle trap that the authors call phase mismatch. Interventions that successfully improve steatohepatitis do not necessarily prevent hepatocellular carcinoma, because the lipid programs driving inflammation in early disease are not the same ones driving malignancy later. Conversely, a tumor vulnerability identified in established cancer may be irrelevant, or even harmful to target, during the precancerous phase. The same pathway can be protective, neutral, or oncogenic depending on when in the continuum it is engaged and in which cell compartment, whether hepatocyte, stellate cell, or immune cell, it is being modulated.

The translational implications are significant but tempered by caution. The review frames future lipid-directed therapy around phase-specific endpoints and biomarker enrichment, meaning trials should stratify patients by disease stage and by molecular markers such as genetic variants in patatin-like phospholipase domain-containing protein 3, transmembrane 6 superfamily member 2, or membrane-bound O-acyltransferase domain containing 7, all of which modulate lipid handling and cancer risk. Approved anti-MASH therapies and standard hepatocellular carcinoma treatments, including immune checkpoint inhibitors and tyrosine kinase inhibitors, remain the only validated options, while most lipid-targeted interventions, from acetyl-CoA carboxylase inhibitors to ferroptosis inducers, are still investigational. The authors also flag environmental contributors such as per- and polyfluoroalkyl substances as emerging risk factors deserving attention.

What the framework ultimately offers is a map. By resolving the MASLD-to-cancer continuum into discrete phases with distinct lipid biology, it gives researchers a way to ask sharper questions: which biomarkers identify patients at each transition point, which interventions should be deployed before transformation rather than after, and how to match a therapy to the specific metabolic dependencies of a given tumor. As fatty liver disease continues its relentless global expansion, this phase-resolved view may prove to be the conceptual tool that finally turns metabolic insight into intercepted cancers.

Subject of Research: Phase-dependent lipid metabolic reprogramming during progression from MASLD/MASH to hepatocellular carcinoma

Article Title: Phase-resolved lipid reprogramming in MASLD/MASH-associated hepatocellular carcinoma: pathogenesis, risk interception, and biomarker-matched therapeutic strategies

Article References: Deng, Y., Chen, T., Hairulajiang, A., Yan, L., Liu, J., & Meng, W. (2026). Phase-resolved lipid reprogramming in MASLD/MASH-associated hepatocellular carcinoma: pathogenesis, risk interception, and biomarker-matched therapeutic strategies. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-09051-8

Image Credits: AI Generated

DOI: 10.1186/s12967-026-09051-8

Keywords: MASLD, MASH, hepatocellular carcinoma, lipid metabolism, de novo lipogenesis, fatty acid oxidation, ferroptosis, biomarkers, liver fibrosis, gut-liver axis, lipotoxicity, translational medicine

The research focused on Group 3 and Group 4 medulloblastoma, molecular subgroups that are driven in part by the potent growth gene MYC and that account for a large share of poor outcomes in patients. These tumours, along with aggressive sonic hedgehog-driven cases, often resist current therapies, and the gold standard treatment regimen of surgical resection combined with intensive chemotherapy and radiotherapy carries severe developmental side effects for young patients. That combination of poor survival and harsh treatment has made the search for new therapeutic angles in these subgroups a pressing clinical priority, and metabolism has emerged as one of the most promising frontiers.

Metabolic reprogramming, the process by which cancer cells rewire their biochemical pathways to fuel relentless growth, is now recognised as a hallmark of tumour progression. One of its most striking features is upregulated lipid metabolism, which allows cancer cells to survive when nutrients become scarce. Rapidly dividing tumours must manufacture or import large quantities of fatty molecules to build new membranes, generate signalling intermediates and produce energy. But handling excess fat is dangerous business: free fatty acids accumulating inside a cell can reach toxic levels, damaging membranes and triggering cell death. Cells therefore need a way to buffer this lipotoxicity, and that is precisely where lipid droplets come in.

Lipid droplets are dynamic intracellular organelles consisting of a neutral lipid core, largely composed of triglycerides and cholesterol esters, wrapped in a phospholipid monolayer studded with proteins. Far from being inert blobs, they protect cells against lipotoxicity by sequestering potentially harmful lipids in a safe, retrievable form, and they can be broken down on demand to release fatty acids for energy production. Yet, as the authors note, their involvement in high-risk medulloblastoma subgroups had remained poorly understood. The new study set out to close that gap using a combination of transcriptomics, the systematic measurement of gene activity, and lipidomics, the comprehensive profiling of the lipid species present in cells, across a panel of medulloblastoma cell lines representing the disease’s molecular diversity.

The results were striking. High-risk medulloblastoma cells, particularly those from Group 3 and Group 4, carried increased numbers of lipid droplets compared with their lower-risk counterparts. Alongside this physical abundance of fat storage, the researchers observed elevated expression of PLIN2, a protein that coats the surface of lipid droplets and is widely used as a molecular marker of their presence. Perilipin 2, as PLIN2 is formally known, helps stabilise droplets and regulates access of fat-breaking enzymes to the stored lipids, so its upregulation indicates not just more droplets but a coordinated cellular programme of lipid storage.

Crucially, the team did not rely on cell lines alone. In an analysis of human tissue microarrays, collections of tiny tumour samples from many patients arranged on a single slide for parallel examination, the increased PLIN2 expression was confirmed in actual patient tissue. This consistency between laboratory models and clinical specimens strengthens the case that lipid droplet accumulation is a genuine feature of high-risk medulloblastoma rather than an artefact of growing tumour cells in a dish, and it raises the possibility that PLIN2 could serve as a prognostic marker, helping clinicians identify the most dangerous tumours.

Digging into the mechanism, the researchers found that the excess droplets arise from an enhanced flux of lipids into the cell from three directions at once: de novo lipogenesis, the internal manufacture of fatty acids from scratch, typically from surplus glucose; cholesterol biosynthesis, the cell’s own production of sterol building blocks; and lipid uptake, the import of fatty molecules from the surrounding environment. When the team delivered various lipids to the cells from outside, they observed an altered maturation of lipid droplets in the high-risk cells, suggesting that these tumour cells handle incoming fat differently from less aggressive ones, processing and packaging it in a distinctive way that supports their survival.

The study’s title points to the functional payoff of all this lipid handling: cholesterol esters stored within lipid droplets play a key role in energy production in Group 3 and Group 4 medulloblastoma cells. In other words, the droplets are not just a waste-disposal system for excess fat; they function as fuel tanks. Stored cholesterol esters can be mobilised and channelled into the cell’s energy-generating pathways, providing a metabolic lifeline that may be especially valuable in the nutrient-deprived conditions that tumours frequently encounter deep within the brain. This reframes lipid droplets as an active component of the cancer cell’s energy economy in these aggressive subgroups.

Altogether, the authors conclude that high-risk Group 3 and Group 4 medulloblastoma cells use lipid droplets in response to their own excessive lipid synthesis, presenting a possible novel therapeutic target and prognostic marker. The therapeutic logic is appealing: if tumour cells depend on droplet-mediated lipid storage and mobilisation to survive, then drugs that block droplet formation, destabilise PLIN2-coated droplets or prevent the release of stored lipids could selectively starve the cancer cells while sparing healthy tissue. Such an approach could complement or reduce the need for the aggressive chemo- and radiotherapy that currently causes severe developmental side effects in children. The work was funded by a grant from the Little Princess Trust, an Academy of Medical Sciences Springboard award and a startup grant from the University of Bath. While the findings are at an early stage and will need to be validated in further preclinical studies before any clinical application, they add medulloblastoma to a growing list of cancers whose vulnerabilities lie not in their genes alone but in the fat they store, and they offer a concrete molecular handle, PLIN2 and the cholesterol ester-filled droplets it marks, on which the next generation of therapies might be built.

Subject of Research: Lipid droplet metabolism and cholesterol ester storage in high-risk medulloblastoma cells

Article Title: Cholesterol esters in lipid droplets play a key role in the energy production of G3/G4 medulloblastoma cells

Article References: Cotton, K., Edwards, C., Papapanagiotou, O., Smirnov, A., Candi, E., Imperiali, B., Agostini, M., Delaidelli, A., López-Duarte, I., Sherin, P., Kuimova, M., Craig, T. J., & Niklison-Chirou, M. V. (2026). Cholesterol esters in lipid droplets play a key role in the energy production of G3/G4 medulloblastoma cells. Cell Death Discovery. https://doi.org/10.1038/s41420-026-03371-w

Image Credits: AI Generated

DOI: 10.1038/s41420-026-03371-w

Keywords: medulloblastoma, lipid droplets, cholesterol esters, PLIN2, cancer metabolism, paediatric brain tumour, lipidomics, de novo lipogenesis, Group 3 medulloblastoma, Group 4 medulloblastoma, MYC, metabolic reprogramming

The condition at the center of this research is known today as metabolic dysfunction-associated steatotic liver disease, or MASLD, a renaming that reflects the growing consensus that the disorder is fundamentally a manifestation of broader metabolic derangement rather than a liver problem in isolation. In its early stage, termed hepatic steatosis, fat droplets accumulate within hepatocytes, the primary working cells of the liver. For many individuals this process remains silent for years, but in a significant fraction it advances to inflammation and scarring, conditions that can progress to cirrhosis and liver cancer. Critically, hepatic fat accumulation is tightly linked to insulin resistance, the metabolic fault line that precedes and drives type 2 diabetes. The study by Koene and colleagues focused precisely on this vulnerable population: individuals with obesity and prediabetes who already had evidence of fatty liver, a group in which effective intervention could alter the trajectory of disease before irreversible damage occurs.

To understand why fructose has emerged as such a compelling target, one must appreciate how differently the body handles this sugar compared with glucose. While virtually every cell in the body can take up and metabolize glucose, fructose is handled primarily by the liver, the small intestine and the kidney. The first and rate-limiting step in fructose metabolism is carried out by an enzyme called ketohexokinase, also known as fructokinase, which rapidly phosphorylates fructose to fructose-1-phosphate. This reaction consumes ATP, the cellular energy currency, and unlike the tightly regulated phosphorylation of glucose, fructokinase operates with little feedback control. The result is a rapid drop in intracellular phosphate and ATP, a transient energy depletion that triggers a cascade of downstream events, including the activation of AMP deaminase and the generation of uric acid, alongside a strong signal promoting de novo lipogenesis, the synthesis of new fat from carbohydrate precursors.

In evolutionary terms, this unregulated metabolic pathway may have been an asset rather than a liability. Fructose is abundant in fruit and honey, foods that were seasonally available to our ancestors. A survival mechanism that efficiently converts fructose into fat stores and induces a mild state of insulin resistance would have helped animals fatten before periods of food scarcity, a strategy famously exploited by hibernating bears and migrating birds. The problem, as Johnson and colleagues have long argued, is that modern diets deliver fructose in refined form, particularly as sucrose and high-fructose corn syrup, in quantities and at a year-round constancy that no foraging ancestor ever encountered. The ancient fattening switch is thereby flipped continuously, promoting fat accumulation in the liver, elevated uric acid, insulin resistance and hypertension, the constellation of abnormalities that defines metabolic syndrome.

Animal studies laid the groundwork for the therapeutic hypothesis. Research published by Ishimoto and colleagues in 2012 demonstrated that mice lacking functional ketohexokinase were protected from fatty liver, weight gain and insulin resistance when consuming fructose, establishing the enzyme as the gateway through which fructose exerts its metabolic damage. Conversely, mice engineered to overexpress the enzyme in the liver or intestine showed heightened susceptibility to these outcomes. Subsequent work, including studies by Gutierrez and colleagues, refined the pharmacology of ketohexokinase inhibition and demonstrated that blocking the enzyme could reduce hepatic fat synthesis and improve metabolic parameters in preclinical models. These findings converged on a clear proposition: if fructose metabolism is a driver of fatty liver, then pharmacologically jamming that pathway might treat the disease even in the face of continued dietary exposure.

Translating that proposition into human medicine required clinical testing, and the road has been building steadily. Early-phase trials of ketohexokinase inhibitors, including studies reported by Kazierad and colleagues in 2021 and by Saxena and colleagues in 2023, evaluated the safety, tolerability and metabolic effects of such compounds in human subjects, providing proof of concept that the enzyme could be safely inhibited in people. The new study by Koene and colleagues extends this line of investigation into the population where the stakes are highest: individuals with obesity, prediabetes and metabolic dysfunction-associated steatotic liver disease. According to the commentary by Johnson, Lanaspa and Tolan, the trial demonstrated that inhibiting fructose metabolism with a ketohexokinase inhibitor improved both hepatic steatosis and insulin resistance in these participants, addressing the two central abnormalities that link fatty liver to future diabetes and cardiovascular risk.

The dual benefit is what makes the result scientifically interesting. Hepatic steatosis and insulin resistance are not merely correlated; they are mechanistically intertwined. Fat accumulation in the liver interferes with insulin signaling, impairing the hormone’s ability to suppress glucose production, while insulin resistance itself promotes further lipogenesis and fat deposition, creating a self-reinforcing loop. A therapy that interrupts fructose metabolism attacks this loop at its entry point, reducing the substrate flux that drives de novo lipogenesis while simultaneously easing the energetic and inflammatory stress that fructose metabolism imposes on hepatocytes. Whether the improvements in insulin sensitivity observed in the trial are entirely secondary to reductions in liver fat, or whether blocking fructokinase also acts through additional pathways such as reduced uric acid generation or effects on the intestinal barrier, remains a question that the commentary suggests will merit further investigation.

Enthusiasm must be tempered by the realities of drug development for a chronic, lifestyle-entangled disease. Ketohexokinase inhibitors do not eliminate fructose from the diet; they blunt the metabolic consequences of its consumption, which raises questions about long-term efficacy, the appropriate patient population, and whether partial inhibition is sufficient or whether complete blockade is required. There are also biological considerations: fructokinase is expressed in tissues beyond the liver, including the kidney and the vasculature, and its complete inhibition could have effects, beneficial or otherwise, that extend beyond hepatic fat. The competing-interest disclosures accompanying the commentary, which note that the authors hold equity in a company developing inhibitors of fructose metabolism, underscore how seriously the pharmaceutical and nutraceutical communities are taking this target, and they also serve as a reminder that independent replication and long-term safety data will be essential before such agents could enter routine clinical practice.

Nevertheless, the significance of the study lies in what it validates conceptually. For decades, the dominant explanation for fatty liver disease centered on dietary fat and overall caloric excess, and the standard prescription has been weight loss through diet and exercise, advice that is effective in principle but notoriously difficult to sustain. The fructose hypothesis reframes the problem as a specific, druggable metabolic pathway, one that can be targeted independently of, or in addition to, behavioral change. If subsequent large-scale trials confirm that ketohexokinase inhibition durably reduces liver fat, improves insulin sensitivity and prevents progression to more severe liver disease, clinicians would gain a mechanism-based therapy for a condition that currently has very few approved pharmacological options. The commentary by Johnson, Lanaspa and Tolan makes the case that the evidence has now reached the threshold where such development is justified, marking a potential turning point in the approach to one of the most common liver diseases in the world.

The broader lesson resonates beyond hepatology. The story of fructose metabolism illustrates how evolutionary physiology, basic enzymology and careful clinical trial design can converge on a therapeutic target hiding in plain sight, in this case a sugar that has been a staple of the human diet for millennia but whose refined, concentrated modern forms interact with an ancient metabolic switch in ways our biology never anticipated. As Koene and colleagues’ findings circulate through the research community, attention will turn to larger and longer trials, to the identification of biomarkers that predict which patients will benefit most, and to the possibility that combination approaches, pairing fructose pathway inhibition with existing metabolic therapies, could deliver even greater benefit. For the millions of people living with fatty livers and prediabetes, the prospect that a well-understood enzymatic bottleneck might be opened to relieve their metabolic burden is a reason for genuine, if measured, optimism.

Subject of Research: Inhibition of fructose metabolism via ketohexokinase blockade as a treatment for metabolic dysfunction-associated steatotic liver disease and insulin resistance

Article Title: Inhibiting fructose metabolism to treat fatty liver

Article References: Johnson, R. J., Lanaspa, M. A., & Tolan, D. R. (2026). Inhibiting fructose metabolism to treat fatty liver. Nature Metabolism. https://doi.org/10.1038/s42255-026-01627-4

Image Credits: AI Generated

DOI: 10.1038/s42255-026-01627-4

Keywords: fructose metabolism, ketohexokinase, fatty liver disease, MASLD, hepatic steatosis, insulin resistance, prediabetes, obesity, de novo lipogenesis, uric acid, metabolic syndrome, clinical trial

The core idea is called lipid metabolic reprogramming. Healthy cells take up and synthesise fats in carefully balanced amounts, using them to build membranes, store energy, and send signals. Cancer cells throw that balance into disarray. To divide relentlessly, a tumour cell must manufacture enormous quantities of new membranes, and the raw material for those membranes is fatty acids and cholesterol. NSCLC cells therefore crank up both the import of lipids from their surroundings and their own internal fat factories, a process known as de novo lipogenesis. The review details how this heightened lipid metabolism satisfies the biosynthetic and energetic demands of the tumour while simultaneously generating signalling molecules that remodel the tumour microenvironment, the complex neighbourhood of immune cells, fibroblasts, and blood vessels in which the cancer lives.

At the molecular level, the machinery of this reprogramming is intricate. Glucose and glutamine that would otherwise be burned for energy are diverted into citrate, which the enzyme ATP citrate lyase, or ACLY, cleaves in the cytoplasm to supply acetyl-CoA for fatty acid synthesis. Acetyl-CoA carboxylase, ACC, then commits this substrate to the fatty acid pathway, and fatty acid synthase, FASN, assembles the growing carbon chains. The master transcriptional regulator behind much of this activity is SREBP, the sterol regulatory element-binding protein, whose activation is promoted by well-known oncogenic drivers in lung cancer, including mutant KRAS, EGFR, ALK, and the transcription factor MYC. Alongside synthesis, tumour cells ramp up lipid uptake through surface proteins such as CD36, the fatty acid transporter family FATP, and receptors for low-density lipoprotein, then stash the cargo in lipid droplets, organelles that act as intracellular fat warehouses. When energy is scarce or the cell is under stress, fatty acid oxidation, driven by enzymes such as carnitine palmitoyltransferase 1, CPT1, releases that stored energy inside mitochondria.

What makes the picture especially compelling is that different histological and molecular subtypes of NSCLC lean on lipids in distinct ways. Lung adenocarcinoma, the most common subtype, frequently shows enhanced de novo lipogenesis tied to KRAS and LKB1 mutations, while squamous cell carcinoma displays its own lipid signatures. The review also highlights how lipid metabolism intersects with resistance to targeted therapies: tyrosine kinase inhibitors that block EGFR or ALK, for example, can be blunted when tumour cells compensate by shifting their energy supply toward fatty acid oxidation. Lipid droplets can also buffer cytotoxic stress, and enzymes such as stearoyl-CoA desaturase 1, SCD1, which converts saturated into monounsaturated fatty acids, help tumour cells manage the lipotoxic and oxidative stresses that chemotherapy and radiotherapy inflict. In other words, the lipid network is not just a growth engine but a survival kit.

Perhaps the most striking section of the review concerns the tumour microenvironment. Lipids do not stay politely inside tumour cells. Tumours release fatty acids, prostaglandins, leukotrienes, and other lipid mediators that re-educate nearly every cell type around them. Tumour-associated macrophages, for instance, can be pushed toward a pro-tumour phenotype by lipid signals such as prostaglandin E2, and in malignant pleural effusions, foamy macrophages laden with ingested lipid accumulate and dampen antitumour immunity. Cancer-associated fibroblasts, meanwhile, can donate lipids to tumour cells, acting as metabolic supply depots. Myeloid-derived suppressor cells exploit fatty acid oxidation to fuel their immunosuppressive activity, and even dendritic cells, the sentinels that launch T cell responses, can be paralysed by lipid accumulation that disrupts their antigen-presenting machinery.

The consequences for T cells, the workhorses of modern cancer immunotherapy, are particularly sobering. The review describes how high lipid levels in the microenvironment drive CD8-positive tumour-infiltrating lymphocytes into an exhausted state, characterised by loss of effector function and upregulation of inhibitory receptors such as PD-1, TIM-3, and LAG-3. Regulatory T cells, by contrast, can thrive on fatty acid oxidation, giving them a metabolic advantage over the antitumour T cells they suppress. Cholesterol and its metabolites add further layers of complexity, with certain cholesterol pools supporting T cell function while oxysterols and related derivatives can promote immune evasion. This metabolic crosstalk offers a mechanistic explanation for why immune checkpoint inhibitors, which have transformed NSCLC treatment, still fail in a substantial fraction of patients: the lipid-rich microenvironment itself may be sabotaging the immune response the drugs are meant to unleash.

All of this biology points toward a tempting therapeutic strategy: starve the tumour of its lipid advantage. Preclinical studies have produced encouraging results with inhibitors of FASN, SCD1, ACC, ACLY, and CPT1, as well as blockers of lipid uptake through CD36 and inhibitors of the mevalonate pathway that supplies cholesterol and lipid-modified signalling proteins. Some of these approaches have also shown synergy with EGFR tyrosine kinase inhibitors and with immune checkpoint blockade in laboratory models, raising hopes for rational combination regimens. The review notes preliminary clinical signals as well. In a phase I study of an FASN inhibitor, 64 percent of patients with KRAS-mutant NSCLC remained progression-free for more than twelve weeks on monotherapy, compared with none of the six patients with KRAS-wildtype disease, a statistically significant difference that hints at a biomarker-defined patient population worth pursuing.

Yet the authors are refreshingly candid about the gap between promise and practice. No lipid-targeted therapy has so far demonstrated clinically meaningful efficacy in unselected NSCLC patients. The reasons are fundamental rather than incidental. Lipid metabolism is essential to every cell in the body, so systemic inhibition risks toxicity to the liver, the immune system, and other lipid-dependent tissues, a problem of target selectivity. Tumour-type specificity matters too: strategies that work in adenocarcinoma may fail in squamous disease, and metabolic redundancy allows tumours to reroute around blocked pathways. Clinical validation has largely been confined to specific molecular subtypes, and the field still lacks the biomarkers needed to identify which patients will benefit from which metabolic intervention. The authors argue that realising the therapeutic potential of lipid targeting will require closing these gaps in selectivity, specificity, and validation, guided by a deeper map of the lipid metabolic networks operating inside individual tumours.

Technology is beginning to provide that map. Advances in mass spectrometry, including gas chromatography-mass spectrometry and high-performance liquid chromatography-tandem mass spectrometry, now allow researchers to profile hundreds of lipid species in tumour samples, while single-cell approaches are revealing how lipid handling differs between individual tumour cells and their neighbours. Such tools could eventually yield lipid biomarkers that predict immunotherapy response, identify metabolic vulnerabilities, and monitor treatment resistance in real time. The review also points to the potential of repurposing existing drugs that touch lipid pathways, from statins that inhibit HMG-CoA reductase to agents affecting lipid signalling, though it cautions that epidemiological signals must be tested in rigorous prospective trials before any clinical recommendations change.

The broader message of this review is that the Warburg-era focus on glucose, while enormously productive, captured only half of the metabolic story of cancer. Lipids are simultaneously fuel, building material, signalling currency, and a language by which tumours speak to their surroundings. In NSCLC, that language appears to shape immune escape, therapy resistance, and disease progression in ways that are only now coming into focus. If the field can convert its extensive preclinical rationale into subtype-specific, biomarker-guided clinical strategies, lipid metabolic reprogramming may finally move from the pages of review articles into the oncology clinic, offering new options for patients whose tumours have exhausted the current arsenal.

Subject of Research: Lipid metabolic reprogramming and its role in non-small cell lung cancer progression, tumour microenvironment crosstalk, and therapeutic targeting

Article Title: Lipid metabolic reprogramming in NSCLC: mechanisms, microenvironment crosstalk, and therapeutic opportunities

Article References: Chen, S., Zhang, H., Luo, Q., You, S., Du, P., Chen, L., Zhang, D., & Meng, R. (2026). Lipid metabolic reprogramming in NSCLC: mechanisms, microenvironment crosstalk, and therapeutic opportunities. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-08854-z

Image Credits: AI Generated

DOI: 10.1186/s12967-026-08854-z

Keywords: non-small cell lung cancer, lipid metabolism, metabolic reprogramming, tumour microenvironment, fatty acid oxidation, de novo lipogenesis, FASN inhibitor, immune checkpoint inhibitors, tumour-associated macrophages, KRAS mutation, therapy resistance, cancer metabolism

The central player in the study is SOX9, short for SRY-box transcription factor 9. Transcription factors are proteins that bind to specific DNA sequences and control whether nearby genes are read into messenger RNA, and SOX9 is well known for its roles in embryonic development and tissue stem cell maintenance. In cancer, SOX9 has previously been implicated in tumor growth and progression, but its involvement in the metabolic transformation of metastatic colorectal cancer cells had remained largely unexplored. The new work positions SOX9 as a direct regulator of de novo lipogenesis, the process by which cells manufacture fatty acids from scratch rather than importing them from the bloodstream.

To dissect this relationship, the researchers combined several complementary approaches. They performed integrated transcriptomic and targeted lipidomic analyses, comparing the gene expression profiles and lipid compositions of cells with and without elevated SOX9. The transcriptomic data revealed changes in the expression of genes involved in fatty acid synthesis, while the lipidomic measurements showed that SOX9 overexpression increased the abundance of fatty acids and other lipid species within the cells. This convergence of genomic and metabolomic evidence provided the first indication that SOX9 overexpression drives fatty acid synthesis and lipid accumulation in colorectal cancer cells.

The team then verified these findings using an arsenal of imaging and analytical techniques. Nile Red staining, a fluorescent dye that preferentially labels neutral lipids, revealed increased lipid content in SOX9-overexpressing cells. Flow cytometry allowed the researchers to quantify lipid accumulation across large cell populations, confirming that the effect was consistent rather than confined to a few cells. Transmission electron microscopy provided ultrastructural evidence, visualizing the intracellular lipid deposits at nanometer resolution. Finally, Nanolive label-free lipid droplet imaging captured the dynamics of lipid storage structures inside living cells. Together, these methods demonstrated that SOX9 overexpression dramatically enhances intracellular lipid deposition, effectively transforming colorectal cancer cells into lipid-storing factories.

The clinical relevance of these observations became apparent when the researchers examined human tissue samples. SOX9 was found to be upregulated in colorectal cancer tissues compared with healthy tissue, and its expression was further enriched in metastatic lesions, the colonies of cancer cells that have established themselves in distant organs. Importantly, patients whose tumors showed high SOX9 levels had poorer outcomes, suggesting that the transcription factor is not merely a bystander in disease progression but a marker, and likely a driver, of aggressive disease.

Functional experiments cemented the link between SOX9-driven lipid production and metastatic behavior. In laboratory assays, cells with elevated SOX9 showed markedly increased migration and invasion, the two cellular behaviors that precede and enable metastatic spread. The team also performed lung metastatic colonization assays in animal models, which measure the ability of circulating cancer cells to seed and grow tumors in the lung. SOX9 overexpression promoted lung metastatic colonization, demonstrating that the lipid-reprogramming effect translates into real metastatic capacity in vivo.

Perhaps the most therapeutically significant result came from the rescue experiments. When the researchers inhibited fatty acid synthase, commonly abbreviated FASN, the enzyme that catalyzes the final steps of fatty acid synthesis, the pro-metastatic effects of SOX9 were significantly attenuated. Migration, invasion and lung colonization all declined when the fat-production line was shut down, even in cells still overexpressing SOX9. This result indicates that FASN sits downstream of SOX9 in the pathway and that the lipid synthesis it drives is not incidental but functionally required for SOX9 to promote metastasis. In principle, this makes the SOX9-FASN axis a metabolic vulnerability that could be targeted with drugs designed to starve metastatic cells of their lipid supply.

Mechanistically, the study went beyond correlation to show how SOX9 controls FASN in the first place. Using CUT&Tag sequencing, a technique that maps where a protein of interest binds across the genome, the researchers identified SOX9 occupancy at sites near the FASN promoter, the regulatory DNA region that controls how strongly the FASN gene is transcribed. This genomic binding evidence was complemented by luciferase reporter assays, in which the FASN promoter was fused to a light-producing reporter gene. When SOX9 was present, reporter activity increased, demonstrating that SOX9 can directly stimulate FASN promoter activity. Further reporter analyses using mutated promoter sequences supported a sequence-dependent mode of regulation, meaning SOX9 requires specific DNA motifs in the proximal FASN promoter to exert its effect, a hallmark of genuine direct transcriptional control rather than an indirect effect mediated through other genes.

The significance of this work lies in how it connects two major themes in modern cancer biology: transcriptional dysregulation and metabolic reprogramming. Cancer cells are known to rewire their metabolism to support rapid growth, survival under stress and dissemination, and increased lipid synthesis has emerged as a recurring feature of aggressive tumors. Lipids are not merely building blocks for new membranes in dividing cells; they also serve as signaling molecules, energy reserves and components of the machinery cells use to change shape and move through tissue. By showing that a developmental transcription factor can impose a lipogenic program on colorectal cancer cells and that this program is required for metastatic colonization, the study offers a coherent explanation for how metabolic flexibility and metastatic competence are coupled at the level of gene regulation.

The findings also suggest practical directions for future research and treatment development. Because FASN inhibition can rescue the metastatic phenotypes induced by SOX9, drugs targeting fatty acid synthase, some of which have already entered clinical evaluation for other cancers, could potentially benefit colorectal cancer patients whose tumors show high SOX9 expression. SOX9 itself, as a transcription factor, has historically been considered a difficult drug target, but its downstream metabolic dependencies offer an alternative point of attack. The study also raises the possibility that SOX9 expression levels could serve as a biomarker to identify patients at high risk of metastasis who might be candidates for metabolic therapies. As with all preclinical research, the results will need to be validated in larger clinical cohorts and tested in appropriately designed trials before they change patient care, but the identification of a defined SOX9-FASN lipid metabolic axis gives researchers a concrete molecular handle on one of the deadliest phases of colorectal cancer.

Subject of Research: SOX9-mediated regulation of lipid metabolism and metastasis in colorectal cancer

Article Title: SOX9 reprograms lipid metabolism via FASN to promote metastasis in colorectal cancer

Article References: Wang, H., Wei, L., Xiang, X., Li, J., Wang, Y., Jiang, Z., Li, X., Li, Y., Pan, Y., & Liang, X. (2026). SOX9 reprograms lipid metabolism via FASN to promote metastasis in colorectal cancer. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-09055-4

Image Credits: AI Generated

DOI: 10.1186/s12967-026-09055-4

Keywords: colorectal cancer, SOX9, FASN, lipid metabolism, metastasis, fatty acid synthesis, de novo lipogenesis, transcription factors, cancer metabolism, CUT&Tag, lung metastasis, Journal of Translational Medicine